| Literature DB >> 35189004 |
Mengzhi Li1, Jingling Zhao1, Ronghua Yang2, Ruizhao Cai1, Xusheng Liu1, Julin Xie1, Bin Shu1, Shaohai Qi1.
Abstract
Owing to recent advances in immunotherapies, the overall survival of patients with skin cutaneous melanoma (SKCM) has increased; however, the 5-year survival rate of metastatic patients remains poor. Skin cutaneous melanoma-upregulated genes were screened via analysis of differentially expressed genes (GSE3189 and GSE46517), and metastasis-related oncogenes were identified via weighted gene coexpression network analysis of the GSE46517 dataset. As confirmed by the Tumor Immune Estimation Resource, we found highly expressed centromere protein F (CENPF) in SKCM and its metastases. Immunostaining of human melanoma tissues demonstrated high CENPF expression. According to the Kaplan-Meier survival curve log-rank test, receiver-operating characteristic curve, and univariate and multivariate analyses, the Cancer Genome Atlas (TCGA) database suggested CENPF be a typical independent predictor of SKCM. The CIBERSORT algorithm classified the types of the immune cells from GSE46517 and showed higher proportion of CD4+ memory-activated T cells in metastatic melanoma. Single-sample gene set enrichment analysis of TCGA data confirmed the correlation between CENPF and activated CD4+ T cells. Centromere protein F was positively correlated with tumor mutational burden and CD4+ memory T cell markers (interleukin [IL]-23A, CD28, and CD62L), negatively associated with memory T cell maintenance factors (IL-7 and IL-15) by correlation analysis. Moreover, immunofluorescence showed high coexpression of CENPF and IL23A, CD4 in melanoma. Upregulated CENPF might lead to premature depletion of CD4+ memory T cells and immunosuppression. Nomogram indicated CENPF clinical predictive value for 1-, 3-, 5-, and 7-year melanoma overall survival. Therefore, CENPF plays a vital role in the progression and metastasis of melanoma and can be an effective therapeutic target.Entities:
Keywords: CD4+ activated T cells; CD4+ memory-activated T cells; CENPF; TMB; cutaneous melanoma; metastasis; nomogram; tumor immunology
Mesh:
Substances:
Year: 2022 PMID: 35189004 PMCID: PMC8990861 DOI: 10.1111/cas.15303
Source DB: PubMed Journal: Cancer Sci ISSN: 1347-9032 Impact factor: 6.716
FIGURE 1The detailed workflow of this study
FIGURE 2Identification of hub genes in skin cutaneous melanoma (SKCM)
Hub genes identified by four ranked methods in cytoHubba
| Ranked methods in cytoHubba | ||||
|---|---|---|---|---|
| MNC | Degree | EPC | MCC | |
| Gene symbol top 10 |
SPP1
ASPM PBK TYMS
TIMP2 HJURP |
SPP1
BMP4
VCAM1 GATA3
TYMS TIMP2 |
SPP1 BMP4
VCAM1
CEP55 ASPM PBK
|
ASPM PBK
TYMS CEP55 HJURP SPAG5
|
Bold gene symbols were the overlap hub genes in top 10 by four ranked methods respectively in cytoHubba.
Abbreviations: Degree, node connect degree; EPC, edge‐percolated component; MCC, maximal clique centrality; MNC, maximum neighborhood component.
FIGURE 3Centromere protein F (CENPF) is associated with skin cutaneous melanoma (SKCM) metastasis and poor survival
Baseline characteristics of skin cutaneous melanoma (SKCM) patients
| Variable |
|
|---|---|
| Sex | |
| Male | 256 (62.4) |
| Female | 154 (37.6) |
| Age | |
| <60 | 211 (51.5) |
| ≥60 | 199 (48.5) |
| Recurrence | |
| Yes | 224 (54.6) |
| No | 186 (45.4) |
| TNM stage | |
| I | 79 (19.3) |
| II | 140 (34.1) |
| III | 167 (40.7) |
| IV | 24 (5.9) |
| Radiation therapy | |
| Yes | 41 (10.0) |
| No | 369 (90.0) |
| Event | |
| Alive | 219 (53.4) |
| Dead | 191 (46.6) |
Univariate and multivariate analyses of various prognostic parameters in patients with skin cutaneous melanoma (SKCM) Cox regression analysis
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Hazard ratio | 95% CI |
| Hazard ratio | 95% CI |
| |
| CENPF | 1.204 | 1.033‐1.402 | 0.017 | 1.157 | 0.988‐1.355 | 0.070 |
| Recurrence | 3.119 | 2.142‐4.543 | <0.001 | 3.165 | 2.154‐4.649 | <0.001 |
| TNM stage | ||||||
| I | 1 | — | 0.001 | <0.001 | ||
| II | 1.580 | 1.049‐2.380 | 0.028 | 1.741 | 1.149‐2.637 | 0.009 |
| III | 2.077 | 1.408‐3.062 | <0.001 | 2.671 | 1.799‐3.968 | <0.001 |
| IV | 2.938 | 1.493‐5.782 | 0.002 | 3.927 | 1.973‐7.816 | <0.001 |
| Radiation therapy | 0.429 | 0.244‐0.755 | 0.003 | 0.504 | 0.284‐0.893 | 0.019 |
Abbreviation: CENPF, centromere protein F.
FIGURE 4Centromere protein F (CENPF) is significantly associated with metastasis
FIGURE 5Assessment of immune cell infiltration in primary and metastatic melanoma
FIGURE 6Centromere protein F (CENPF) is associated with cluster of differentiation 4 (CD4)+ memory T cell markers and negatively associated with CD4+ memory T cell survival regulators in melanoma
FIGURE 7Centromere protein F (CENPF) nomogram and survival curve validation by nomogram scores